CAMBRIDGE, Mass. (September 4, 2014) - Induced pluripotent stem cells (iPSCs)--adult cells reprogrammed back to an embryonic stem cell-like state--may hold the potential to cure damaged nerves, regrow limbs and organs, and perfectly model a patient's particular disease. Yet through the reprogramming process, these cells can acquire serious genetic and epigenetic abnormalities that lower the cells' quality and limit their therapeutic usefulness.
When the generation of iPSCs was first reported in 2006, efficiency was paramount because only a fraction of a percentage of reprogrammed cells successfully became cell lines. Accordingly, the stem cell field focused on reprogramming efficiency to boost the pool of cells that could be studied. However, as scientists gained an increased understanding of the reprogramming process, they realized that myriad variables, including the ratio of reprogramming factors and the reprogramming environment, can also greatly affect cell quality.
Now researchers working in the lab of Whitehead Institute Founding Member Rudolf Jaenisch together with scientists from the Hebrew University have determined that the reprogramming factors themselves impact the reprogramming efficiency and the quality of the resulting cells. Their work is described in the current issue of the journal Cell Stem Cell.
"Postdoctoral researcher Yosef Buganim and Research Scientist Styliani Markoulaki show that a different combination of reprogramming factors may be less efficient than the original, but can produce much higher quality iPSCs," says Jaenisch, who is also a professor of biology at MIT. "And quality is a really important issue. At this point, it doesn't matter if we get one colony out of 10,000 or one out of 100,000 cells, as long as it is of high quality."
To make iPSCs, scientists expose adult cells to a cocktail of genes that are active in embryonic stem cells. iPSCs can then be pushed to differentiate into almost any other cell type, such as nerve, liver, or muscle cells. Although the original combination of Oct4, Sox2, Klf4, and Myc (OSKM) efficiently reprograms cells, a relatively high percentage of the resulting cells have serious genomic aberrations, including aneuploidy, and trisomy 8, which make them unsuitable for use in clinical research.
Using bioinformatic analysis of a network of 48 genes key to the reprogramming process, Buganim and Markoulaki designed a new combination of genes, Sall4, Nanog, Esrrb, and Lin28 (SNEL). Roughly 80% of SNEL colonies made from mouse cells were of high quality and passed the most stringent pluripotency test currently available, the tetraploid complementation assay. By comparison, only 20-30% of high quality OSKM passed the same test. Buganim hypothesizes that SNEL reprograms cells better because, unlike OSKM, the cocktail does not rely on a potent oncogene like Myc, which may be causing some of the genetic problems. More importantly, the cocktail does not rely on the potent key master regulators Oct4 and Sox2 that might abnormally activate some regions in the adult cell genome.
To better understand why some reprogrammed cells are of high quality while others fall short, Buganim and Markoulaki analyzed SNEL colonies down to the genetic and epigenetic level. On their DNA, SNEL cells have deposits of the histone protein H2AX in locations very similar to those in ESCs, and the position of H2AX seems to predict the quality of the cell. The researchers believe this characteristic could be used to quickly screen for high quality colonies.
But for all of its promise, the current version of SNEL seems unable to reprogram human cells, which are generally more difficult to manipulate than mouse cells.
"We know that SNEL is not the ideal combination of factors," says Buganim, who is currently a Principal Investigator at Hebrew University in Jerusalem. "This work is only a proof of principle that says we must find this ideal combination. SNEL is an example that shows if you use bioinformatics tools you can get better quality. Now we should be able to find the optimal combination and try it in human cells to see if it works."
This work is supported by the Israeli Centers of Research Excellence (I-CORE) and the National Institutes of Health (NIH; grants HD 045022 and R37CA084198). Jaenisch is an adviser to Stemgent and a cofounder of Fate Therapeutics.
Written by Nicole Giese Rura
Rudolf Jaenisch's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a professor of biology at Massachusetts Institute of Technology.
"The developmental potential of iPSCs is greatly influenced by reprogramming factor selection"
Cell Stem Cell, September 4, 2014.
Yosef Buganim (2,8,*), Styliani Markoulaki (1,*), Niek van Wietmarschen (3), Heather Hoke (1,4), Tao Wu (5), Kibibi Ganz (1), Batool Akhtar-Zaidi (1), Yupeng He (6), Brian J. Abraham (1), David Porubsky (3), Elisabeth Kulenkampff (1), Dina A. Faddah (1,4), Linyu Shi (1), Qing Gao (1), Sovan Sarkar (1), Malkiel Cohen (1), Johanna Goldmann (1), Joseph R. Nery (6), Matthew D. Schultz (6), Joseph R. Ecker (6), Andrew Xiao (5), Richard Young (1,4,7), Peter M. Lansdorp (3,7) and Rudolf Jaenisch (1,4,7,8).
1. Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
2. Department of Developmental Biology and Cancer Research, the Institute for Medical Research Israel-Canada, the Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel
3. European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, AV Groningen 9713, the Netherlands
4. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
5. Yale Stem Cell Center, Yale University, New Haven, CT 06520, USA
6. Genomic Analysis Laboratory, the Salk Institute for Biological Studies, La Jolla, CA 92037, USA
7. Skolkovo Institute of Science and Technology (Skoltech), Novaya str. 100, Skolkovo Moscow Region 143025, Russia
* Co-first authors